Holen Sie sich die Stockscreener-App
681.58
1.68%
-11.65
Vorhandelsmarkt:
685.00
3.42
+0.50%
Schlusskurs vom Vortag:
$693.23
Offen:
$705.34
24-Stunden-Volumen:
1.05M
Relative Volume:
1.30
Marktkapitalisierung:
$74.90B
Einnahmen:
$13.85B
Nettoeinkommen (Verlust:
$4.65B
KGV:
16.87
EPS:
40.41
Netto-Cashflow:
$3.32B
1W Leistung:
-2.20%
1M Leistung:
-7.90%
6M Leistung:
-37.22%
1J Leistung:
-26.64%
1-Tages-Spanne:
$680.89
$707.48
1-Wochen-Bereich:
$666.25
$717.37
52-Wochen-Spanne:
$666.25
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Clear Harbor Asset Management LLC Buys 3,006 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Lmcg Investments LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
404 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Mechanics Bank Trust Department - MarketBeat
MassMutual Private Wealth & Trust FSB Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Regeneron Pharmaceuticals (REGN) Faces Securities Class - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman - GlobeNewswire Inc.
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Cove Private Wealth LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
2025-01-20 | REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm - GuruFocus.com
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to - The Bakersfield Californian
ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron - GlobeNewswire
Moss Adams Wealth Advisors LLC Buys 923 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Monarch Capital Management Inc. Acquires 549 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’ - Insider Monkey
AdvisorNet Financial Inc Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
B & T Capital Management DBA Alpha Capital Management Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Boston Common Asset Management LLC - MarketBeat
Avanza Fonder AB Makes New $7.41 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - StreetInsider.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Procyon Advisors LLC - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron - GlobeNewswire
Robbins LLP Urges REGN Stockholders with Large Losses to - GlobeNewswire
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Woodstock Corp Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Kilgore News Herald
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact L - GuruFocus.com
2025-01-17 | REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REGN | Press Release - Stockhouse Publishing
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN - Morningstar
Outlook Wealth Advisors LLC Invests $305,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report - Nasdaq
Fifth Third Wealth Advisors LLC Has $783,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance
UBS Downgrades Regeneron Pharmaceuticals (REGN) - MSN
What to Expect From Regeneron Pharmaceuticals's Q4 2024 Earnings Report - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - Stockhouse Publishing
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron Executives Sued for Medicare Overbilling, Stock Drop - Bloomberg Law
Regeneron Pharmaceuticals, Inc. Securities Fraud Class - GlobeNewswire
UBS cuts rating on Regeneron stock amid Eylea uncertainty - Investing.com
What To Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report - Barchart
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers - AOL
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by UBS Group - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Connective Portfolio Management LLC - MarketBeat
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):